<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="article-commentary" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">38516</article-id><article-id pub-id-type="doi">10.7554/eLife.38516</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Insight</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group><subj-group subj-group-type="sub-display-channel"><subject>Alzheimer’s Disease</subject></subj-group></article-categories><title-group><article-title>The two shapes of the Tau protein</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-1118"><name><surname>Kelly</surname><given-names>Jeffery W</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-8943-3395</contrib-id><email>jkelly@scripps.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Jeffery W Kelly</bold> is in the Departments of Chemistry and Molecular Medicine, The Scripps Research Institute, La Jolla, United States</p></bio></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Chemistry</institution><institution>The Scripps Research Institute</institution><addr-line><named-content content-type="city">La Jolla</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Molecular Medicine</institution><institution>The Scripps Research Institute</institution><addr-line><named-content content-type="city">La Jolla</named-content></addr-line><country>United States</country></aff></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>10</day><month>07</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>7</volume><elocation-id>e38516</elocation-id><history><date date-type="received" iso-8601-date="2018-06-25"><day>25</day><month>06</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2018-06-25"><day>25</day><month>06</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Kelly</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Kelly</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-38516-v1.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="commentary-article" xlink:href="10.7554/eLife.36584"/><abstract><p>Tau proteins can convert from an inert shape to a misfolded shape that seeds the growth of fibers that contribute to the pathology of Alzheimer’s disease.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>tau</kwd><kwd>Alzheimer's disease</kwd><kwd>protein aggregates</kwd><kwd>seeding</kwd><kwd>amyloid fibers</kwd><kwd>transthyretin</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Tau proteins can convert from an inert shape to a misfolded shape that seeds the growth of fibers that contribute to the pathology of Alzheimer's disease.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text><p><bold>Related research article</bold> Mirbaha H, Chen D, Morozova OA, Ruff KM, Sharma A, Liu X, Goodarzi M, Pappu RV, Colby DW, Mirzaei H, Joachimiak LA, Diamond MI. 2018. Inert and seed-competent tau monomers suggest structural origins of aggregation. <italic>eLife</italic> <bold>7</bold>:e36584. doi: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.7554/eLife.36584">10.7554/eLife.36584</ext-link></p></boxed-text><p>Most of the time, proteins fold into a single stable shape to perform their role in the body, but occasionally they can adopt a different conformation. These 'misfolded' proteins can be associated with a range of degenerative conditions known as amyloid disorders, which includes the transthyretin amyloidoses as well as Alzheimer’s and Parkinson's diseases. This is because the misfolded proteins go on to stick together and form toxic insoluble aggregates, for example ‘amyloid’ fibers, that accumulate inside cells. One such protein is Tau, which aggregates in people with Alzheimer’s disease. It is thought that the misfolded Tau proteins and the various Tau aggregates, including amyloid fibers, contribute to the onset of Alzheimer’s disease (<xref ref-type="bibr" rid="bib5">Eisele et al., 2015</xref>), but these processes are not fully understood.</p><p>Inside a cell, the harmful aggregation process is believed to begin with a ‘seed’, a template that can trigger the assembly of a given protein. These seeds are thought to be crucial in the spread of the disease. The hypothesis is that seeds can convert the normally folded protein into an aggregate of the same protein, before cells release them into the environment for neighboring cells to take up (<xref ref-type="bibr" rid="bib6">Eisenberg and Jucker, 2012</xref>). This could be how diseases linked to the Tau protein, such as Alzheimer’s, propagate from one cell to another; there, the aggregates would travel through the brain using the connections between neurons (<xref ref-type="bibr" rid="bib3">Clavaguera et al., 2009</xref>; <xref ref-type="bibr" rid="bib11">Sanders et al., 2014</xref>). While the identity of the seeds remains unclear, until now, almost all scientists have believed that they are an assembly of a given individual misfolded protein. Now, in eLife, Marc Diamond of the University of Texas Southwestern Medical Center (UTSW) and colleagues – including Hilda Mirbaha as first author – report the existence of a stable of form of an individual Tau protein that can start the aggregation process on its own (<xref ref-type="bibr" rid="bib9">Mirbaha et al., 2018</xref>).</p><p>The fact that the seed may not be an assembly of a misfolded protein, but instead be a single protein – a monomer – with a different conformation had only been suggested twice before. In 2005, a study proposed that a change in the conformation of a Tau monomer had a critical role in triggering the process of aggregation (<xref ref-type="bibr" rid="bib2">Chirita et al., 2005</xref>). And in 2011, it was hypothesized that the aggregation of the huntingtin protein, which is involved in another amyloid disorder known as Huntington’s disease, could start with a single protein (<xref ref-type="bibr" rid="bib8">Kar et al., 2011</xref>). However, in these two studies the monomer that could initiate the seeding process was not isolated and studied. Despite robust data interpretation, many in the scientific community dismissed the idea of monomeric seeds, reluctant to challenge the widely ingrained concept that they are instead an assembly of a misfolded protein.</p><p>So far, Tau was considered to be an intrinsically disordered protein – more like a flexible noodle than a protein with a well-defined and stable, three-dimensional structure (<xref ref-type="bibr" rid="bib12">Schweers et al., 1994</xref>). Instead, Mirbaha et al. show that the Tau protein can fold into two distinct and fairly well-defined conformations. One of these shapes is stable, nontoxic and does not easily aggregate; the other acts as a seed and can help to convert another ‘harmless’ Tau monomer into a misfolded Tau that will form toxic aggregates by seeding or self-assembly. In addition, Tau can very slowly change from the inert to the seed-competent conformation. It is known that small molecules can bind to the inert conformation of proteins that are prone to misfolding, and thus prevent the conformational change that leads to amyloid diseases (<xref ref-type="bibr" rid="bib7">Johnson et al., 2012</xref>).</p><p>For example, transthyretin is another protein with two ways of folding, and whose toxic conformation damages various nervous systems, as well as the heart. However, drugs known as kinetic stabilizers can slow down the degenerative process by increasing the population of the properly folded conformation. More precisely, three placebo-controlled clinical trials showed that small molecules, such as the drugs tafamidis and diflunisal, can bind to the non-pathogenic form of transthyretin and stabilize it, which prevents the protein from converting into the conformation that initiates aggregates and leads to degenerative pathologies (<xref ref-type="bibr" rid="bib4">Coelho et al., 2012</xref>; <xref ref-type="bibr" rid="bib1">Berk et al., 2013</xref>; <xref ref-type="bibr" rid="bib10">Rosenblum et al., 2018</xref>). This suggests that it should be possible to fashion similar kinetic stabilizers for the Tau protein, and offer better treatment for diseases such as Alzheimer’s.</p></body><back><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berk</surname> <given-names>JL</given-names></name><name><surname>Suhr</surname> <given-names>OB</given-names></name><name><surname>Obici</surname> <given-names>L</given-names></name><name><surname>Sekijima</surname> <given-names>Y</given-names></name><name><surname>Zeldenrust</surname> <given-names>SR</given-names></name><name><surname>Yamashita</surname> <given-names>T</given-names></name><name><surname>Heneghan</surname> <given-names>MA</given-names></name><name><surname>Gorevic</surname> <given-names>PD</given-names></name><name><surname>Litchy</surname> <given-names>WJ</given-names></name><name><surname>Wiesman</surname> <given-names>JF</given-names></name><name><surname>Nordh</surname> <given-names>E</given-names></name><name><surname>Corato</surname> <given-names>M</given-names></name><name><surname>Lozza</surname> <given-names>A</given-names></name><name><surname>Cortese</surname> <given-names>A</given-names></name><name><surname>Robinson-Papp</surname> <given-names>J</given-names></name><name><surname>Colton</surname> <given-names>T</given-names></name><name><surname>Rybin</surname> <given-names>DV</given-names></name><name><surname>Bisbee</surname> <given-names>AB</given-names></name><name><surname>Ando</surname> <given-names>Y</given-names></name><name><surname>Ikeda</surname> <given-names>S</given-names></name><name><surname>Seldin</surname> <given-names>DC</given-names></name><name><surname>Merlini</surname> <given-names>G</given-names></name><name><surname>Skinner</surname> <given-names>M</given-names></name><name><surname>Kelly</surname> <given-names>JW</given-names></name><name><surname>Dyck</surname> <given-names>PJ</given-names></name><collab>Diflunisal Trial Consortium</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial</article-title><source>JAMA</source><volume>310</volume><fpage>2658</fpage><lpage>2667</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.283815</pub-id><pub-id pub-id-type="pmid">24368466</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chirita</surname> <given-names>CN</given-names></name><name><surname>Congdon</surname> <given-names>EE</given-names></name><name><surname>Yin</surname> <given-names>H</given-names></name><name><surname>Kuret</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Triggers of full-length tau aggregation: a role for partially folded intermediates</article-title><source>Biochemistry</source><volume>44</volume><fpage>5862</fpage><lpage>5872</lpage><pub-id pub-id-type="doi">10.1021/bi0500123</pub-id><pub-id pub-id-type="pmid">15823045</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clavaguera</surname> <given-names>F</given-names></name><name><surname>Bolmont</surname> <given-names>T</given-names></name><name><surname>Crowther</surname> <given-names>RA</given-names></name><name><surname>Abramowski</surname> <given-names>D</given-names></name><name><surname>Frank</surname> <given-names>S</given-names></name><name><surname>Probst</surname> <given-names>A</given-names></name><name><surname>Fraser</surname> <given-names>G</given-names></name><name><surname>Stalder</surname> <given-names>AK</given-names></name><name><surname>Beibel</surname> <given-names>M</given-names></name><name><surname>Staufenbiel</surname> <given-names>M</given-names></name><name><surname>Jucker</surname> <given-names>M</given-names></name><name><surname>Goedert</surname> <given-names>M</given-names></name><name><surname>Tolnay</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Transmission and spreading of tauopathy in transgenic mouse brain</article-title><source>Nature Cell Biology</source><volume>11</volume><fpage>909</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1038/ncb1901</pub-id><pub-id pub-id-type="pmid">19503072</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coelho</surname> <given-names>T</given-names></name><name><surname>Maia</surname> <given-names>LF</given-names></name><name><surname>Martins da Silva</surname> <given-names>A</given-names></name><name><surname>Waddington Cruz</surname> <given-names>M</given-names></name><name><surname>Planté-Bordeneuve</surname> <given-names>V</given-names></name><name><surname>Lozeron</surname> <given-names>P</given-names></name><name><surname>Suhr</surname> <given-names>OB</given-names></name><name><surname>Campistol</surname> <given-names>JM</given-names></name><name><surname>Conceição</surname> <given-names>IM</given-names></name><name><surname>Schmidt</surname> <given-names>HH</given-names></name><name><surname>Trigo</surname> <given-names>P</given-names></name><name><surname>Kelly</surname> <given-names>JW</given-names></name><name><surname>Labaudinière</surname> <given-names>R</given-names></name><name><surname>Chan</surname> <given-names>J</given-names></name><name><surname>Packman</surname> <given-names>J</given-names></name><name><surname>Wilson</surname> <given-names>A</given-names></name><name><surname>Grogan</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial</article-title><source>Neurology</source><volume>79</volume><fpage>785</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182661eb1</pub-id><pub-id pub-id-type="pmid">22843282</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisele</surname> <given-names>YS</given-names></name><name><surname>Monteiro</surname> <given-names>C</given-names></name><name><surname>Fearns</surname> <given-names>C</given-names></name><name><surname>Encalada</surname> <given-names>SE</given-names></name><name><surname>Wiseman</surname> <given-names>RL</given-names></name><name><surname>Powers</surname> <given-names>ET</given-names></name><name><surname>Kelly</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Targeting protein aggregation for the treatment of degenerative diseases</article-title><source>Nature Reviews Drug Discovery</source><volume>14</volume><fpage>759</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1038/nrd4593</pub-id><pub-id pub-id-type="pmid">26338154</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenberg</surname> <given-names>D</given-names></name><name><surname>Jucker</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The amyloid state of proteins in human diseases</article-title><source>Cell</source><volume>148</volume><fpage>1188</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.022</pub-id><pub-id pub-id-type="pmid">22424229</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>SM</given-names></name><name><surname>Connelly</surname> <given-names>S</given-names></name><name><surname>Fearns</surname> <given-names>C</given-names></name><name><surname>Powers</surname> <given-names>ET</given-names></name><name><surname>Kelly</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug</article-title><source>Journal of Molecular Biology</source><volume>421</volume><fpage>185</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2011.12.060</pub-id><pub-id pub-id-type="pmid">22244854</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kar</surname> <given-names>K</given-names></name><name><surname>Jayaraman</surname> <given-names>M</given-names></name><name><surname>Sahoo</surname> <given-names>B</given-names></name><name><surname>Kodali</surname> <given-names>R</given-names></name><name><surname>Wetzel</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Critical nucleus size for disease-related polyglutamine aggregation is repeat-length dependent</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>18</volume><fpage>328</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1992</pub-id><pub-id pub-id-type="pmid">21317897</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirbaha</surname> <given-names>H</given-names></name><name><surname>Chen</surname> <given-names>D</given-names></name><name><surname>Morozova</surname> <given-names>OA</given-names></name><name><surname>Ruff</surname> <given-names>KM</given-names></name><name><surname>Sharma</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Goodarzi</surname> <given-names>M</given-names></name><name><surname>Pappu</surname> <given-names>RV</given-names></name><name><surname>Colby</surname> <given-names>DW</given-names></name><name><surname>Mirzaei</surname> <given-names>H</given-names></name><name><surname>Joachimiak</surname> <given-names>LA</given-names></name><name><surname>Diamond</surname> <given-names>MI</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inert and seed-competent tau monomers suggest structural origins of aggregation</article-title><source>eLife</source><volume>7</volume><elocation-id>e36584</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.36584</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenblum</surname> <given-names>H</given-names></name><name><surname>Castano</surname> <given-names>A</given-names></name><name><surname>Alvarez</surname> <given-names>J</given-names></name><name><surname>Goldsmith</surname> <given-names>J</given-names></name><name><surname>Helmke</surname> <given-names>S</given-names></name><name><surname>Maurer</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>TTR (Transthyretin) Stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis</article-title><source>Circulation: Heart Failure</source><volume>11</volume><elocation-id>e004769</elocation-id><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.117.004769</pub-id><pub-id pub-id-type="pmid">29615436</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname> <given-names>DW</given-names></name><name><surname>Kaufman</surname> <given-names>SK</given-names></name><name><surname>DeVos</surname> <given-names>SL</given-names></name><name><surname>Sharma</surname> <given-names>AM</given-names></name><name><surname>Mirbaha</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>A</given-names></name><name><surname>Barker</surname> <given-names>SJ</given-names></name><name><surname>Foley</surname> <given-names>AC</given-names></name><name><surname>Thorpe</surname> <given-names>JR</given-names></name><name><surname>Serpell</surname> <given-names>LC</given-names></name><name><surname>Miller</surname> <given-names>TM</given-names></name><name><surname>Grinberg</surname> <given-names>LT</given-names></name><name><surname>Seeley</surname> <given-names>WW</given-names></name><name><surname>Diamond</surname> <given-names>MI</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Distinct tau prion strains propagate in cells and mice and define different tauopathies</article-title><source>Neuron</source><volume>82</volume><fpage>1271</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.04.047</pub-id><pub-id pub-id-type="pmid">24857020</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schweers</surname> <given-names>O</given-names></name><name><surname>Schönbrunn-Hanebeck</surname> <given-names>E</given-names></name><name><surname>Marx</surname> <given-names>A</given-names></name><name><surname>Mandelkow</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure</article-title><source>The Journal of Biological Chemistry</source><volume>269</volume><fpage>24290</fpage><lpage>24297</lpage><pub-id pub-id-type="pmid">7929085</pub-id></element-citation></ref></ref-list></back></article>